CD274 and small cell lung carcinoma: In a real-world study by Yang (33), the combination of anti-angiogenic drugs and immunotherapy (anti-PD-1/PD-L1) demonstrated promising antitumor activity and tolerability in patients with extensive-stage small cell lung cancer (ES-SCLC).